Living long-term with advanced GIST on tyrosine kinase inhibitors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an international, multicentre observational program with two parts: a retrospective cross-sectional component and a prospective cohort (registry). The retrospective arm focuses on patients with unresectable or metastatic GIST treated with TKIs for five years or more to test the relevance and applicability of patient-reported outcome instruments and identify GIST-specific survivorship issues. The prospective cohort enrolls adults with advanced or metastatic GIST who have received TKIs for at least two years across multiple centres in Europe and China and follows them over time. Data collection combines validated questionnaires on health-related quality of life, coping, and financial impact with clinical information extracted from medical records to document long-term outcomes, treatment patterns, and survivorship challenges.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older (no upper age limit);
* Advanced or metastatic GIST, diagnosis of GIST must be histologically proven;
* Treated with TKIs (eg. sunitinib, regorafenib, avapritinib, ripretinib) for at least 2 years; TKI treatment ongoing; interruptions up to 3 months are allowed;
* Able to read and answer questionnaires;
* Able to provide informed consent.

Exclusion Criteria:

* Patients receiving TKI in an adjuvant treatment setting.
* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before inclusion the study.
* Patients who are too ill (death is imminent), as determined by the referring health care professional.

Where it's running

• Antoni van Leeuwenhoek
  Amsterdam, North Holland, Netherlands Recruiting

Study contacts

• Principal investigator: Winette V van der Graaf, Prof. dr. — Antoni van Leeuwenhoek
• Study coordinator: Tessa van Amerongen, MSc, Drs.
• Email: t.v.amerongen@nki.nl
• Phone: +31 020 512 9111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Robotic removal of stomach GISTs in difficult anatomic locations

  This study will try robotic radical surgery to remove localized gastric GISTs 2–5 cm located at special anatomic sites in adults who have not received prior neoadjuvant therapy.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07405125

• GIST Patient Registry for real-world insights

  This registry collects medical information from people with GIST to see how the disease behaves in real life and to help improve care.

  Recruiting The Life Raft Group · Wayne, New Jersey · NCT07697248

• ctDNA-guided precision care for lung, GIST, colorectal, biliary, and ovarian cancers

  This trial tests a blood test that looks for tumor DNA in patients with several cancers to help guide personalized treatment decisions.

  Recruiting Royal Marsden NHS Foundation Trust · London · NCT07673861

• AI using endoscopic ultrasound and white-light endoscopy to diagnose upper GI mesenchymal tumors

  This project will test a multimodal AI tool that uses endoscopic ultrasound, white-light endoscopy images, and clinical data to help diagnose and risk-stratify upper gastrointestinal subepithelial tumors in adults who have had endoscopy.

  Recruiting Huazhong University of Science and Technology · Wuhan, Hubei · NCT07078136

• International registry for very rare childhood tumors

  This project will collect detailed medical information to see how clinical and biological features affect outcomes in children and adolescents with very rare tumors.

  Recruiting Azienda Ospedaliera di Padova · Padova, Italy · NCT07072143

• Combining ziftomenib and imatinib for advanced gastrointestinal stromal tumors

  This study is testing whether combining two medications, ziftomenib and imatinib, can help adults with advanced gastrointestinal stromal tumors who haven't responded well to imatinib alone.

  Recruiting at 32 sites Phase 1 Kura Oncology, Inc. · Birmingham, Alabama and 31 other locations · NCT06655246

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.